Pluristem Therapeutics, Inc. (NASDAQ:PSTI) Traded Well Above Its 50 Day Moving Average


The stock is trading at $1.46 quite a bit higher than $1.20, the stock’s 50 day moving average and which is significantly higher than the 200 day moving average of $1.28. The 50 day moving average went up $0.26 or +21.99% and the 200 day average went up by +13.76%. Trading volume for Pluristem Therapeutics, Inc. was 1,005K in the last trading session. Volume was up 735.38% over the stocks average daily volume.

Traders are feeling more bullish on Pluristem Therapeutics, Inc. as indicated by the change in short interest. The company saw a fall in short interest of -10.17% as of the latest report on August 31, 2017. Short shares decreased 108,126 over that period. With short interest at 955,254 and short average daily volume at 255,417, days to cover is 4.0 and the short interest percentage is 0.01% as of August 31.

The following firms have recently changed their position in PSTI. As of the end of the quarter Ubs Group Ag had acquired 592,557 shares growing its stake by 274.5%. The value of the total investment in Pluristem Therapeutics, Inc. went from $265,000 to $1,035,000 a change of $770,000 quarter to quarter. As of quarter end Jane Street Group, LLC had bought a total of 122,471 shares growing its position 112.5%. The value of the company’s investment in Pluristem Therapeutics, Inc. increased from $134,000 to $296,000 increasing 120.9% for the reporting period.

Focused Wealth Management, Inc bolstered its holdings by buying 10,000 shares an increase of 100.0%. Focused Wealth Management, Inc now controls 20,000 shares worth $26,000. The value of the position overall is up by 116.7%. Psagot Investment House Ltd. divested its ownership by shedding 3,719 shares a decrease of 34.1% as of 06/30/2017. Psagot Investment House Ltd. currently owns 7,175 shares valued at $9,000. The total value of its holdings decreased 30.8%.

In the latest earnings report the EPS was $-0.32 and is estimated to be $-0.40 for the current year with 97,473,000 shares currently outstanding. Analysts expect next quarter’s EPS to be $-0.09 with next year’s EPS projected to be $-0.37.

Pluristem Therapeutics Inc., launched on May 10, 2001, is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Business’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. The Business’s operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Business’s products include PLX-PAD and PLX R18. The Business’s PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Business’s PLX products are administered using a standard needle and syringe. The Business’s PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women’s health diseases..